Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06154252
Other study ID # CAB-201-002
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date December 20, 2023
Est. completion date July 2028

Study information

Verified date April 2024
Source Cabaletta Bio
Contact Cabaletta Bio
Phone 12677593100
Email clinicaltrials@cabalettabio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy


Description:

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, and IMNM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date July 2028
Est. primary completion date July 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age =18 and =65 - A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria - Diagnosis of DM, ASyS, IMNM based on the presence of serum myositis-specific antibodies - Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography - Presence of muscle weakness Exclusion Criteria: - Contraindication to leukapheresis - History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites - Active infection requiring medical intervention at screening - Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections. - Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures - Significant lung or cardiac impairment - Previous CAR T cell therapy - Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CAB-201 following preconditioning with fludarabine and cyclophosphamide
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Locations

Country Name City State
United States University of Kansas Medical Center Kansas City Kansas
United States Vanderbilt University Medical Center Nashville Tennessee
United States University of California Irvine Orange California
United States Oregon Health & Science University Portland Oregon
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Cabaletta Bio

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate adverse events reported by subjects Incidence and severity of AEs Up to 28 days after CABA-201 infusion
Secondary To evaluate adverse events and laboratory abnormalities Incidence and severity of AEs, including changes in laboratory values and vital signs Up to 156 weeks
Secondary To characterize the pharmacodynamics (PD) Levels of B cells in the blood Up to 156 weeks
Secondary To characterize the pharmacokinetics (PK) Levels of CABA-201-positive T cells in the blood Up to 156 weeks
Secondary To evaluate disease-related biomarkers of muscle inflammation Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum Up to 156 weeks
Secondary To evaluate autoantibody -related biomarkers Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum Up to 156 Weeks
Secondary To evaluate efficacy Total Improvement Score (0 to 100, with higher scores indicating greater improvement) based on the Core Set Measures Up to 156 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05833711 - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy Phase 2
Completed NCT01906372 - Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Phase 2
Completed NCT01813617 - Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis N/A
Completed NCT01165008 - Anakinra in Myositis Phase 2/Phase 3
Completed NCT00004357 - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Phase 2
Recruiting NCT05832034 - Add-on Intravenous Immunoglobulins in Early Myositis Phase 2
Recruiting NCT05979441 - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy Phase 3
Not yet recruiting NCT05027152 - Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties N/A
Active, not recruiting NCT04723303 - Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) Early Phase 1
Completed NCT03267277 - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Phase 2/Phase 3
Recruiting NCT05437263 - A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Phase 3
Active, not recruiting NCT04044690 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) Phase 3
Recruiting NCT05523167 - A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Phase 2/Phase 3
Not yet recruiting NCT06004817 - Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Recruiting NCT03324152 - Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis N/A
Completed NCT02043548 - Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Phase 2
Completed NCT03414086 - Predictor of Clinical Response to Acthar in Myositis
Completed NCT04628936 - Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. Phase 2
Recruiting NCT03293615 - Exercise Capacity of Patients With Dermatomyosis N/A
Completed NCT06002750 - Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Inflammation